Michael Moore Amends Viemed Healthcare Stake on Feb 15

TL;DR

**Michael Moore just updated his 13D filing for Viemed Healthcare, Inc. on Feb 15, signaling a change in his ownership details.**

AI Summary

Michael Moore filed an Amendment No. 2 to Schedule 13D with the SEC on February 15, 2024, regarding his beneficial ownership in Viemed Healthcare, Inc. The filing updates previous disclosures concerning his stake in the company's Common Shares, No Par Value, identified by CUSIP 92663R105. This amendment indicates a change in the information previously reported by Mr. Moore, though the specific nature of the change (e.g., share count, intent) is not detailed in this snippet.

Why It Matters

Schedule 13D/A filings signal changes in significant shareholder positions or intentions, which can influence investor perception and stock performance. This amendment indicates an updated stance from a major holder, Michael Moore, on Viemed Healthcare, Inc.

Risk Assessment

Risk Level: medium — While the filing itself is routine for a significant shareholder, the specific details of the amendment (e.g., increase/decrease in stake, change in activist intent) are not provided, making the impact on the stock uncertain.

Key Players & Entities

• Michael Moore (person) — Filing Person
• Viemed Healthcare, Inc. (company) — Subject Company
• SEC (company) — Regulatory Body

FAQ

Filing Documents

• sc13dmmoore-021524.htm (SC 13D/A) — 70KB
• 0001781905-24-000002.txt ( ) — 71KB

Security and Issuer

Item 1. Security and Issuer. This Amendment No. 2 ("Amendment No. 2") amends the Schedule 13D initially filed on February 12, 2021, as amended on May 18, 2023 (collectively, the "Schedule 13D"), and is filed to report changes in the beneficial ownership of Common Shares by Michael Moore. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

Identity and Background

Item 2. Identity and Background.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows a. This Schedule 13D is filed by Michael Moore, a natural person ("Moore"), and Moore Faster LLC, a Louisiana limited liability company ("MF LLC") (collectively, the "Reporting Persons"). b. The business address of Moore is 625 E. Kaliste Saloom Rd, Lafayette, Louisiana 70508 and the business address of MF LLC is 625 E. Kaliste Saloom Rd, Lafayette, Louisiana 70508 . c. As of February 15, 2024, Moore is employed as the President by the Issuer, and the principal business of MF LLC is to invest in securities and other assets . d. During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). e. During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order (i) enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or (ii) finding a violation with respect to such laws. f. Moore is a citizen of the United States of America and MF LLC is a Louisiana limited liability company.

Identity and Background

Item 4. Identity and Background.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows Each of the Reporting Persons holds the Shares as reported herein for investment purposes and does not have any specific plans or proposals regarding the Issuer in such Reporting Person's capacity as a holder of Common Shares. Each of the Reporting Persons does not have any current plans or proposals which relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows 4 (a) – (b) The percent of class provided for the Reporting Persons is made in accordance with Rule 13d-3(d) of the Securities Act of 1933, as amended (the "Securities Act") and is based on 38,756,636 Common Shares outstanding as of February 15, 2024 based on information provided by the Issuer. Moore is the beneficial owner of 2,520,918 Common Shares, which amount includes 1,722,614 shares held by MF LLC and 671,962 shares issuable upon the exercise of options that are vested or will vest within 60 days. Moore has the sole power to vote or to direct the vote of and the sole power to dispose of or to direct the disposition of 798,304 Common Shares. Each of Moore and MF LLC shares the power to vote or to direct the vote of or to dispose or to direct the disposition of 1,722,614 Common Shares. Moore owns 50% of the ownership units in MF LLC and serves as a general manager of MF LLC. The information provided on the cover pages with respect to the beneficial ownership of Moore is incorporated herein by reference. (c) On January 4, 2021, an award of 99,243 restricted share units granted to Moore vested, which entitled Moore with the right to receive one Common Share per restricted stock unit. The Issuer withheld 30,917 Common Shares to satisfy Moore's tax obligation resulting from the vesting of the 99,243 restricted share units. On January 4, 2021, an award of 43,513 stock options awards granted to Moore vested. On January 17, 2021, an award of 121,299 stock options awards granted to Moore vested. On January 21, 2021, Moore received a grant of 120,584 options to acquire Common Shares under the 2020 Incentive Plan, which award vests in three equal annual installments beginning on the first anniversary of the grant date. On January 17, 2022, an award of 121,299 stock options awards granted to Moore vested. On January 18, 2022, Moore received a grant of 85,410 options to acqu

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits. The following exhibit is added to the exhibits listed in Item 7 of the Schedule 13D 99.1 Joint Filing Agreement dated as of February 15, 2024 among the Reporting Persons. 6 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date February 15, 2024 s Michael Moore Michael Moore Moore Faster LLC s Michael Moore Michael Moore, General Manager 7 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the shares of common stock of Viemed Healthcare, Inc. dated as of February 15, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. s Michael Moore Michael Moore Moore Faster LLC s Michael Moore Michael Moore, General Manager 8

View Full Filing

View this SC 13D/A filing on SEC EDGAR